A cost-effectiveness approach to drug subsidy and pricing in Australia

Donald J. Birkett, Andrew S. Mitchell, Peter McManus

    Research output: Contribution to journalArticle

    61 Citations (Scopus)

    Abstract

    The Australian government offers its citizens subsidies on a select list of pharmaceuticals. For a drug to qualify for inclusion on this list, its manufacturer must demonstrate that the drug is both clinically effective and cost-effective. In part, this measure, along with others, was introduced to improve clinical and economic outcomes. Although this evidence-based system has provided transparency and consistency in decision making about which drugs will be covered, it may not have contained the rate of increase in drug costs.

    Original languageEnglish
    Pages (from-to)104-114
    Number of pages11
    JournalHealth Affairs
    Volume20
    Issue number3
    DOIs
    Publication statusPublished - May 2001

    Fingerprint Dive into the research topics of 'A cost-effectiveness approach to drug subsidy and pricing in Australia'. Together they form a unique fingerprint.

  • Cite this